Narsoplimab Exceeds Expectations Across High-Risk HSCT-TMA Subtype

May 14, 2021

Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody

Twice Daily Poziotinib Helps Lesson Toxicity in EGFR or HER2 exon 20-Positive NSCLC

May 14, 2021

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.

Deciding Between Active Surveillance and Targeted Therapy in BRCA+ Prostate Cancer

May 14, 2021

Leonard G. Gomella, MD, discusses deciding between active surveillance and precision medicine in mutated prostate cancer.

Case 1: Role of Symptomatic Improvement in Overall Outcome in MF

May 14, 2021

Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.

Case 1: Treatment Approaches for High Risk P. Vera

May 14, 2021

Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.

Case 2: REACH3 Trial

May 14, 2021

The experts discuss the REACH3 trial in steroid-refractory chronic GVHD and what they hope to see in the future of treating chronic GVHD.

Case 2: Steroid-Refractory Chronic GVHD

May 14, 2021

The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.

Genetic Testing Informs Treatment Decisions in Melanoma

May 14, 2021

Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.

Special Episode: Oncology After COVID-19

May 14, 2021

In season 2, episode 4 of “Targeted Talks,” Benjamin O. Anderson, MD, FACS, discussed the lessons learned from the COVID-19 pandemic, and preparation for a post-COVID America.

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

May 14, 2021

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.

Ibrutinib Plus Venetoclax Is a Potential Second-line Regimen in MCL

May 14, 2021

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Pembrolizumab Achieves Prespecified Event-Free Survival in High-Risk TNBC

May 13, 2021

Patients with high-risk, early-stage triple-negative breast cancer in the phase 3 KEYNOTE-522 trial of pembrolizumab plus chemotherapy after surgery demonstrated statistically significant event-free survival.